Objectives: To evaluate and compare the efficacy and safety of the combination of raloxifene and alendronate with those of monotherapies in elderly women with osteoporosis. Methods: Sixty-two postmenopausal women (mean age 63.5 ± 0.5 years) attending gynecologic osteoporosis clinics with established osteoporosis were randomly allocated to one of four treatment groups and monitored for 3 years. All patients enrolled in this study, including those in the control group (n = 14), received 1.0 g elemental calcium and 400 units of vitamin D per day. The raloxifene group (n = 16) received raloxifene 60 mg (Evista ® ) per day; alendronate group (n = 17) received low-dose (5 mg) alendronate with calcitriol 0.5 μg (Maxmarvil ® ) per day; and the combination therapy group (n = 15) received both raloxifene 60 mg and low-dose (5 mg) alendronate with calcitriol 0.5 µg. Bone mineral density (BMD) was measured in the lumbar spine and hip before and after 3 years of treatment.
Introduction
The impact of osteoporosis is most pronounced in elderly women who have the highest risk of fracture. 1, 2 Several medications are effective in decreasing the incidence of osteoporotic fractures. Vertebral and nonvertebral fractures can be reduced by 30% to 65% by the administration of anticatabolic agents (e.g. raloxifene, alendronate, and risedronate). 3, 4 Although the relationship between bone mineral density (BMD) and fracture reduction is not linear, 5~7 17, 18 are examples of the estrogen-agonist effects of raloxifene.
Compared with the stimulation observed after estrogen therapies, raloxifene did not increase endometrial thickness 19, 20 or breast density 21 were observed with raloxifene, which demonstrated the estrogen-antagonist effects on these tissues.
Owing to these contrasting actions, the present study was performed to test the hypothesis that the addition of alendronate would have an independent, additive effect on the changes in BMD and bone turnover markers observed with raloxifene therapy when these therapies were administered in combination.
This 3-year prospective randomized study was carried out to determine whether the combination therapy of raloxifene and low dose alendronate was efficacious and safe, in comparison with monotherapies in elderly women with osteoporosis.
Materials and Methods

Patient selection
The present study was conducted at the Department of 
BMD measurement
The BMD was determined using a prodigy series X-ray tube housing assembly (LUNAR; GE Medical System, 
Results
The characteristics of the women enrolled in the study were as follows: mean age of 63. . There were no differences in baseline characteristics among the groups (Table 1) . Of the 70 women enrolled, 62 (88.6%) completed the study, there were no differences among the groups in the overall discontinuation rate or in the reasons for discontinuation.
In patients who received the combined therapy, BMD increased in the lumbar spine and the hip by 7.2% (P < 0.001) and 4.8% (P < 0.001) at 3 years. For patients in the alendronate group, the increases were 6.7% (P < 0.001) and 3.1% (P < 0.01) respectively, for the raloxifene group, the increases were 4.36% (P < 0.001) and 1.9% (P < 0.05) in the vertebrae and femora, respectively; however, the BMD of patients in the control group decreased by 1.81% (P < 0.05) and 1.6% (P < 0.05), respectively, after 3 years. Patients who received the combination therapy had significantly higher BMD in both the vertebrae femora (P < 0.01) in comparison to that in those treated with raloxifene or alendronate individually ( Table 2) .
A significant decline in urine NTx/Cr was observed at week 4 in the raloxifene and the alendronate group, whereas in the raloxifene only group, a significant decline in urine NTx/Cr occurred at month 9. By the end of 36 months, urine NTx/Cr decreased by 47.7% in the raloxifene and the alendronate group (P = 0.001) compared with a 22.1% increase in the raloxifene group). A significant decline in serum OC level occurred at month 3 in the raloxifene and the alendronate group, whereas a similar decline was observed at month 6 in the raloxifene group. By the end of 36 months, serum OC decreased by 48.6% in the raloxifene and the alendronate group (P < 0.001) compared with a 1.6% increase in the raloxifene group) (Fig. 1 ).
There were no statistically significant differences among the groups with respect to the incidences of any of the adverse events that were associated with either raloxifene or alendronate therapy. More side effects occurred with longer duration of treatment. Pain in the bones and arthralgia increased after 3 years of treatment (Table 3) . In the past, combination therapy consisted of the combination of two anticatabolic agents, such as HRT and a bisphosphonate. The combination of HRT and etidronate was shown to increase BMD compared to that reported with either agent alone. 22 In two studies of postmenopausal women with low bone mass, the HRT and alendronate combination was associated with larger BMD increases than that observed with HRT alone.
11,23
However, HRT is no longer recommended for the first- Values obtained at randomization were expressed as mean ± standard deviation, and n represents number of women randomized (except for BMD measurements) PL: placebo, RLX: raloxifene, ALN: alendronate, BMI: body mass index, BMD: bone mineral density Most importantly, the additional costs of with combination Changes in bone markers are known to occur early in the treatment course. 27 In our study, a significant decrease in urine NTx/Cr from baseline was observed at week 4 in the raloxifene and the alendronate group, whereas it occurred at month 9 in the raloxifene group. A significant decrease in serum OC level from baseline occurred at month 3 in the raloxifene and the alendronate group, whereas it was observed at month 6 in the raloxifene-only group.
Our findings suggest that the use of the raloxifene and the alendronate group is effective in slowing the rate of bone turnover, and in our study its effect occurred early and persisted throughout the treatment period. Although raloxifene group also slowed the bone turnover rate, this occurred later with lesser magnitude in our study (Fig. 1) .
In summary, raloxifene and alendronate individually, 
